| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.90▲ | 6.24▲ | 6.06▲ | 4.90▲ | 3.96▲ |
| MA10 | 6.67▲ | 5.82▲ | 6.43▲ | 4.11▲ | 3.38▲ |
| MA20 | 6.21▲ | 7.04▲ | 5.68▲ | 3.60▲ | 2.82▲ |
| MA50 | 5.78▲ | 4.97▲ | 4.14▲ | 3.11▲ | 2.24▲ |
| MA100 | 6.63▲ | 3.86▲ | 3.36▲ | 2.65▲ | 2.58▲ |
| MA200 | 4.80▲ | 3.02▲ | 2.71▲ | 2.21▲ | 2.87▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.100▲ | -0.060▼ | -0.062▼ | 0.373▲ | 0.317▲ |
| RSI | 75.938▲ | 58.066▲ | 59.003▲ | 93.857▲ | 91.643▲ |
| STOCH | 84.196▲ | 65.447 | 21.480 | 70.109 | 80.694▲ |
| WILL %R | 0.000▲ | -16.300▲ | -71.738 | -69.683 | -65.906 |
| CCI | 107.929▲ | 154.729▲ | 17.057 | 154.783▲ | 458.100▲ |
|
Wednesday, October 22, 2025 10:06 AM
Armata Pharmaceuticals (ARMP) stock soars 300% after the company announces promising Phase 2 trial results for its AP-SA02 antibacterial agent. Read more here.
|
|
Wednesday, October 22, 2025 09:39 AM
Investing.com -- Armata Pharmaceuticals (NYSE American:ARMP) stock surged 95% following the announcement of positive Phase 2a clinical trial results for its bacteriophage treatment targeting ...
|
|
Wednesday, October 22, 2025 09:02 AM
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/10/25 | 5.97 | 7.10 | 5.06 | 7.10 | 992,700 |
| 22/10/25 | 3.50 | 16.34 | 3.47 | 7.05 | 12,990,200 |
| 21/10/25 | 3.49 | 3.50 | 3.45 | 3.47 | 11,700 |
| 20/10/25 | 3.42 | 3.50 | 3.40 | 3.48 | 8,300 |
| 17/10/25 | 3.49 | 3.49 | 3.40 | 3.40 | 4,908 |
| 16/10/25 | 3.45 | 3.50 | 3.30 | 3.49 | 8,800 |
| 15/10/25 | 3.17 | 3.4993 | 3.14 | 3.41 | 25,371 |
| 14/10/25 | 3.32 | 3.32 | 3.19 | 3.28 | 8,300 |
| 13/10/25 | 3.30 | 3.30 | 3.16 | 3.30 | 8,746 |
| 10/10/25 | 3.19 | 3.29 | 3.17 | 3.17 | 11,400 |
|
|
||||
|
|
||||
|
|